It was reported that p-STAT1 expression may be a potential biomarker for ICB in breast cancer patients.32 Therefore, we speculated that GBP2 may affect the efficacy of immunotherapy in pMMR/MSS CRC. This evidence concerns the gene STAT1 and breast carcinoma.